Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Filings indexed 205 across all filing types
Latest filing 2024-09-25 Report Publication Anno…
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short regulatory announcement (812 characters) regarding the scheduling and holding of an Investor Relations (IR) meeting. It provides details such as the date, location, target audience, and purpose of the meeting. According to the 'Menu vs Meal' rule, since this is an announcement of an event/presentation rather than the presentation material itself, and it is a short regulatory notice, it falls under the category of a general regulatory filing or announcement.
2024-09-25 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an upcoming Investor Relations (IR) meeting (기업설명회). It provides the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it is a regulatory disclosure filed with the Korea Exchange (KRX), it falls under the category of a general regulatory filing or announcement regarding corporate activities.
2024-08-19 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'NeoPharm' covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business overviews, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-12 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (잠정실적) for Neopharm, detailing quarterly financial performance (revenue, operating profit, net income) for the period ending 2024-06-30. It provides key financial highlights and is clearly an initial announcement of financial results rather than a full report or a mere announcement of a report's publication. Therefore, it fits the definition of an Earnings Release (ER). Q2 2024
2024-08-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (purchases) made by a director (Kim Yang-soo) of the company Neopharm. This type of filing is a standard regulatory requirement for reporting insider trading or changes in share ownership by company executives, which corresponds to the 'Director's Dealing' category.
2024-06-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This document details the acquisition of shares by an executive (Lim Woo-jae) of NeoPharm. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2024-06-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.